

GAMMACAN INTERNATIONAL INC  
Form 8-K  
August 16, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**August 16, 2007**  
(Date of Earliest Event Reported)

**GAMMACAN INTERNATIONAL, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**0-32835**  
(Commission  
File Number)

**33-0956433**  
(IRS Employer  
Identification No.)

**39 Jerusalem St.**  
**Kiryat Ono 55423 Israel**  
(Address of principal executive offices)

**(972) (3) 738-2616** (Registrant's telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events**

On August 7, 2007, a press release was issued by GammaCan International, Inc. (the Registrant) (OTCBB: GCAN) disclosing GammaCan's receipt from the U.S. Food and Drug Administration of orphan drug designation for its lead anti-cancer immunotherapy, VitiGam for the treatment of Stage IIB to Stage IV metastatic melanoma.

A copy of GammaCan's press release is attached as Exhibit 99.1

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 16, 2007

**GAMMACAN INTERNATIONAL, INC.**

By: /s/ Patrick N.J. Schnegelsberg

Name: Patrick N.J. Schnegelsberg

Title: Chief Executive Officer

---